New antibody ALTB-268 enters human testing for ulcerative colitis

NCT ID NCT07350577

Ongoing Disease control Sponsor: AltruBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called ALTB-268, a monoclonal antibody, in 24 healthy volunteers. The main goal is to check safety and how the body processes the drug. If it passes safety checks, it may later be tested in people with ulcerative colitis to see if it can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALTB-268 (a monoclonal antibody)
What this could lead to: If successful, this could lead to a new treatment option for ulcerative colitis, helping control the disease and reduce symptoms.
What could go wrong: This is a very early Phase 1 trial in only 24 healthy people, not patients. It only tests safety and dosing, not whether it works for UC. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Syneos Health Clinical Research Services, LLC

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.